HITLAB has announced a strategic partnership with Jeeva Clinical Trials, a U.S.-based digital research platform provider offering a human-centric, AI-native eClinical cloud designed for decentralized and hybrid clinical trials.

In a statement issued on January 29, 2026, HITLAB said that as clinical research continues to shift toward “distributed models,” sponsors and contract research organizations face increasing complexity in deploying AI-enabled infrastructure that is operationally “sound, scalable, and accessible” to patients. According to the statement, the partnership brings together Jeeva’s unified eClinical platform and HITLAB’s “independent research, validation, and market development” expertise to support responsible adoption across the life sciences ecosystem.

Jeeva’s platform supports automated clinical trial workflows and remote patient participation across a range of therapeutic areas, including oncology and rare diseases, according to the statement. As part of the partnership, HITLAB will assist Jeeva’s U.S. expansion by independently evaluating the platform’s usability and operational effectiveness, enhancing evidence-based communications, and enabling strategic engagement with biopharmaceutical sponsors, contract research organizations, and investors.

“The next phase of clinical research depends on AI-native platforms that are not only technically advanced, but also trustworthy, usable, and aligned with real-world research operations,” said Stan Kachnowski, PhD, Chair and Co-Founder of HITLAB. “This partnership reflects HITLAB’s commitment to independently evaluating emerging research infrastructure while helping high-potential platforms responsibly scale in the U.S. market.”

“HITLAB will also work with Jeeva to synthesize existing platform insights and customer experiences into clear, publishable materials and market-facing narratives,” added the statement noting these will be shared during HITLAB’s May 2026 Innovators Summit in New York City.

“Decentralized trials require connected infrastructure that is both operationally rigorous and patient-centered,” said Harsha Rajasimha, PhD, Founder and CEO of Jeeva Clinical Trials. “Working with HITLAB allows us to independently validate how our platform performs in real-world research environments while accelerating engagement with sponsors and CROs seeking integrated, AI-enabled solutions that reduce cost and complexity.”

Related posts:

‘There are Plenty of Problems Begging to be Solved in Rare Diseases’ Indo-US Bridging RARE Summit 2025 to Convene Global Experts and Advocates at George Mason University ISPL Season 3 Trials Begin Across 101 Cities, 4.4 Million Players Vie for Spot in Grand 2026 Edition IndoUSrare and George Mason University Host Global Summit Advancing Rare-Disease Research and Collaboration